Use of cyclosporine in uterine transplantation
- PMID: 22132302
- PMCID: PMC3216255
- DOI: 10.1155/2012/134936
Use of cyclosporine in uterine transplantation
Abstract
Uterine transplantation has been proposed as a possible solution to absolute uterine factor infertility untreatable by any other option. Since the first human attempt in 2000, various teams have tried to clarify which immunosuppressant would be most suitable for protecting the allogeneic uterine graft while posing a minimal risk to the fetus. Cyclosporine A (CsA) is an immunosuppressant widely used by transplant recipients. It is currently being tested as a potential immunosuppressant to be used during UTn. Its effect on the mother and fetus and its influence upon the graft during pregnancy have been of major concern. We review the role of CsA in UTn and its effect on pregnant transplant recipients and their offspring.
References
-
- Del Priore G, Schlatt S, Wagner R, Reynoso E, Malanowska-Stega J. Uterus transplantation: on the edge. Seminars in Reproductive Medicine. 2011;29(1):55–60. - PubMed
-
- Nair A, Stega J, Smith JR, Del Priore G. Uterus transplant: evidence and ethics. Annals of the New York Academy of Sciences. 2008;1127:83–91. - PubMed
-
- Aarts JWM, Van Empel IWH, Boivin J, Nelen WL, Kremer JAM, Verhaak CM. Relationship between quality of life and distress in infertility: a validation study of the Dutch FertiQoL. Human Reproduction. 2011;26(5):1112–1118. - PubMed
-
- Merril JP, Murray JE, Harrison JH, Guild WR. Successful homotransplantation of the human kidney between identical twins. Journal of the American Medical Association. 1956;160(4):277–282. - PubMed
LinkOut - more resources
Full Text Sources
